NCT03639623View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions

Liver Transplant; ComplicationsNAFLD

Interventions

DRUG

Saroglitazar

Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors

lead

Zydus Therapeutics Inc.

INDUSTRY

NCT03639623 - Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) | Biotech Hunter | Biotech Hunter